Interleukin inhibitors

Anakinra is recommended in accordance with NICE TA 685 as an option for treating adult-onset Still's disease and systemic juvenile idiopathic arthritis (paediatric).

Anakinra is approved in K&M for restricted use for adult patients with Secondary Haemophagocytic Lymphohistiocytosis (sHLH)in accordance with the NHSE Commissioning Policy. It is for consultant initiation following approval from the HLH regional MDT.

NICE has NOT approved the use of anakinra for the treatment of rheumatoid arthritis. 

Drugs in this class require Blue-teq funding form to be completed. 

Tocilizumab has been approved and commissioned by NHSE for Cytokine Release Syndrome (CRS) following CAR-T or bispecific antibody treatment. Refer to guidelines in your Trust for this indication. This requires Blu-teq completion.